+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor



Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor



Experimental Hematology 16(7): 594-602



Bone marrow cells from patients with leukemia, myelodysplastic syndromes, cancer, and other disorders on a phase I clinical trial with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) were assessed in vitro for numbers of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, and for growth patterns (colony-to-cluster ratio) of CFU-GM, cycling rates of CFU-GM, and responsiveness in vitro to colony-stimulating and colony-inhibiting factors. The colony-to-cluster ratio of CFU-GM and the dose-response curves of CFU-GM to stimulation by rhGM-CSF in vitro did not change during the clinical trial. However, the percentage of CFU-GM in DNA synthesis, which is a measure of the proliferative rates of these cells, determined by the high specific activity tritiated thymidine kill technique in vitro, was markedly enhanced in a reversible fashion after administration in vivo of rhGM-CSF. The increased cycling rates of CFU-GM were consistent with the induced increase in neutrophil counts in these patients that has been reported elsewhere. Additionally, marrow CFU-GM from patients given rhGM-CSF in vivo were increased in sensitivity to inhibition in vitro by recombinant human H-subunit (acidic) ferritin in two of eight cases, and were increased in sensitivity to inhibition by lower dosages of recombinant human tumor necrosis factor alpha in all patients evaluated. The sensitivity of CFU-GM to inhibition in vitro by recombinant human interferon gamma and prostaglandin E1 did not change during the clinical trial. These studies demonstrate that the rhGM-CSF is having an effect on CFU-GM in the patients on the phase I clinical trial. This information may be of significance in planning future clinical studies combining rhGM-CSF with chemotherapy and/or other biotherapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040231275

Download citation: RISBibTeXText

PMID: 3260558


Related references

Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Experimental Hematology 17(5): 455-459, 1989

Effect of recombinant human growth factors: recombinant human interleukin-6, recombinant human granulocyte-macrophage colony-stimulating-factor and recombinant human erythropoietin on normal human hematopoietic progenitor cells. Zhonghua Nei Ke Za Zhi 33(5): 298-301, 1994

The effect of recombinant granulocyte-macrophage colony-stimulating factor (leucomax) on the growth of hematopoietic progenitor cells in patients with haemoblastoses. Eksperimental'naya Onkologiya 18(2): 152-157, 1996

Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: Detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery. Medical and Pediatric Oncology 25(5): 365-371, 1995

Recombinant human granulocyte-colony stimulating factor and recombinant human macrophage-colony stimulating factor synergize in vivo to enhance proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in mice. Journal of Cellular Biochemistry 38(2): 127-136, 1988

Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. Journal of Clinical Oncology 14(1): 277-286, 1996

Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non hodgkin's lymphoma blood and bone marrow progenitor growth studies a phase ii eastern cooperative oncology group trial. Blood 78(3): 830-837, 1991

Macrophage colony-stimulating factor in cooperation with transforming growth factor-beta1 induces the differentiation of CD34+ hematopoietic progenitor cells into Langerhans cells under serum-free conditions without granulocyte-macrophage colony-stimulating factor. Journal of Investigative Dermatology 120(2): 256-265, 2003

Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 75(12): 2305-2310, 1990

A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biology of Blood and Marrow Transplantation 10(12): 848-857, 2004

Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 79(10): 2572-2577, 1992

Effect of a combined exposure to cytosine arabinoside bryostatin 1 and recombinant granulocyte macrophage colony stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia 6(5): 432-439, 1992

The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 81(7): 1863-1870, 1993

Chemotherapy with granulocyte colony stimulating factor (G-CSF) alone versus granulocyte colony stimulating factor (G-CSF) plus granulocyte-macrophage stimulating factor (GM-CSF) for hematopoietic progenitor cell mobilization in patients with relapsed non-hodgkin's lymphomas (NHLs).. 2007

Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Japanese Journal of Clinical Oncology 24(4): 205-211, 1994